Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: Results for N-Nitroso Carvedilol Impurity-1 (NNCI) impurity observed to be above the FDA-recommended limit of NMT 4.0 ppm
| Brand name | CARVEDILOL |
| Generic name | CARVEDILOL |
| Active ingredient(s) | CARVEDILOL |
| Distributed by / for | Major Pharmaceuticals, Indianapolis, IN, 46268, USA |
| NDC | 0904-7307-61 |
| Full product label | Carvedilol Tablets USP, 12.5 mg, 100- Tablets, (10x10) cartons, Rx Only, Packaged and distributed by Major Pharmaceuticals, Indianapolis, IN, 46268, USA, NDC 0904-7307-61 |
| Recalling firm | The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories |
| Distribution | Product was distributed nationwide within the United States. |
| Quantity | 26,628 cartons |
| Recall initiated | 2025-08-20 |
| Report date | 2025-08-27 |
| Recall completed | — |
| Recall number | D-0594-2025 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | La Vergne TN United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗